The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacokinetics (Peak Plasma Concentration (Cmax) ) of PEG-rhGH with present and new preparation
Timeframe: 0 hours -192 hours post-administration
Pharmacokinetics (Area under the concentration-time curve from time zero to time infinity (AUC0-inf)) of PEG-rhGH with present and new preparation
Timeframe: 0 hours -192 hours post-administration
Pharmacokinetics (Area under the concentration-time curve from time zero to the time of the last quantifiable (AUC0-last)) of PEG-rhGH with present and new preparation
Timeframe: 0 hours -192hours post-administration
Safety and tolerability (Number of participants with treatment-related adverse events)
Timeframe: up to approximately 30 days